Leader Cold And Flu label

Leader Cold And Flu

Leader Cold And Flu Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no side effect or adverse reaction information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

There is current no usage information for this drug.

History

There is currently no drug history available for this drug.

Other Information

There is currently no other information available for this drug.

Leader Cold And Flu Manufacturers

  • Leader Cold And Flu | Remedyrepack Inc.
    No Recall

    Leader Cold And Flu | Remedyrepack Inc.

    Leader Cold And Flu | Remedyrepack Inc.

     

    800 mg every 4 hours orally, 5 times daily for 7 to 10 days.

     

     

    200 mg every 4 hours, 5 times daily for 10 days.

     

    400 mg 2 times daily for up to 12 months, followed by re-evaluation. Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily.

    The frequency and severity of episodes of untreated genital herpes may change over time. After 1 year of therapy, the frequency and severity of the patient’s genital herpes infection should be re-evaluated to assess the need for continuation of therapy with acyclovir.

     

    200 mg every 4 hours, 5 times daily for 5 days. Therapy should be initiated at the earliest sign or symptom (prodrome) of recurrence.

     

     

    20 mg/kg per dose orally 4 times daily (80 mg/kg/day) for 5 days. Children over 40 kg should receive the adult dose for chickenpox.

     

    800 mg 4 times daily for 5 days.

    Intravenous acyclovir is indicated for the treatment of varicella-zoster infections in immunocompromised patients.

    When therapy is indicated, it should be initiated at the earliest sign or symptom of chickenpox. There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms.

     

    In patients with renal impairment, the dose of acyclovir should be modified as shown in Table 3:

    Table 3. Dosage Modification for Renal Impairment

    Creatinine

    Adjusted Dosage Regimen

    Normal Dosage

    Regimen

    Clearance

    (mL/min/1.73 m2)

    Dose

    (mg)

    Dosing Interval

    200 mg every 4 hours

    >10

    200

    every 4 hours, 5x daily

    0-10

    200

    every 12 hours

    400 mg every 12 hours

    >10

    0-10

    400

    200

    every 12 hours

    every 12 hours

    800 mg every 4 hours

    >25

    800

    every 4 hours, 5x daily

    10-25

    800

    every 8 hours

    0-10

    800

    every 12 hours

     

    For patients who require hemodialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis.

     

    No supplemental dose appears to be necessary after adjustment of the dosing interval.